These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29017497)

  • 1. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
    Kitao N; Miyoshi H; Furumoto T; Ono K; Nomoto H; Miya A; Yamamoto C; Inoue A; Tsuchida K; Manda N; Kurihara Y; Aoki S; Nakamura A; Atsumi T;
    Cardiovasc Diabetol; 2017 Oct; 16(1):125. PubMed ID: 29017497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
    Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
    Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes.
    Tasci I; Naharci MI; Bozoglu E; Safer U; Aydogdu A; Yilmaz BF; Yilmaz G; Doruk H
    Endocr Metab Immune Disord Drug Targets; 2013 Sep; 13(3):256-63. PubMed ID: 23848558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
    Hermans M; Van Gaal L; Rézette I; Daci E; MacDonald K; Denhaerynck K; Vancayzeele S; De Meester L; Clemens A; Yee B; Abraham I
    Prim Care Diabetes; 2016 Dec; 10(6):425-433. PubMed ID: 27388795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
    Halimi S; Schweizer A; Minic B; Foley J; Dejager S
    Vasc Health Risk Manag; 2008; 4(3):481-92. PubMed ID: 18827867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
    Shelbaya S; Rakha S
    Curr Med Res Opin; 2017 May; 33(5):797-801. PubMed ID: 28303721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2009 Mar; 64(3):161-7. PubMed ID: 19418936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.
    Cakirca M; Karatoprak C; Zorlu M; Kiskac M; Kanat M; Cikrikcioglu MA; Soysal P; Hursitoglu M; Camli AA; Erkoc R; Abdul-Ghani M
    Drug Des Devel Ther; 2014; 8():239-43. PubMed ID: 24627624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
    Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
    Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.
    Chatterjee S; Chatterjee S
    Am J Ther; 2015; 22(3):195-8. PubMed ID: 23665884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E; Dotta F; Jia Y; Goodman M
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
    He YL; Sabo R; Picard F; Wang Y; Herron J; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.